3 February 2021

According to a peer-reviewed paper in the Lancet, Russia’s Sputnik V vaccine reported 91.6% efficacy in fighting the Covid-19 disease in Phase III trials. Experts believe that the results diminish the transparency concerns over the jab, which has already been rolled out in Russia and a few other countries. The vaccine is named after the Soviet-era satellite.  The current study suggests that Sputnik V is one of the top-performing vaccines alongside Moderna and Pfizer/BioNTech vaccines, which have also reported over 90% efficacy.

Novavax announced a memorandum of understanding  with the Canadian Government to manufacture NVX-CoV2373, the company’s protein-based Covid-19 vaccine candidate, in Canada. Establishing a manufacturing foothold in Canada will be critical for meeting the urgent need for vaccines in the country. Novavax intends to produce its vaccine at the National Research Council’s Biologics Manufacturing Centre in Montréal once Health Canada approvals are granted to the vaccine and the facility.

Ocugen and Bharat Biotech announced a definitive agreement to manufacture, supply, as well as market the latter’s’s COVAXIN, an advanced stage inactivated Covid-19 vaccine candidate in the US market. As per the terms of the agreement, Bharat Biotech will supply initial doses to Ocugen and also support the technology transfer for manufacturing, while Ocugen will hold exclusive rights to develop, seek regulatory emergency use approval and commercialise the vaccine in the US.

Edesa Biotech has received approximately C$14m (US$11m) from the Government of Canada to complete its Phase II part of the Phase II/III clinical study for EB05, its investigational drug, for treating hospitalised Covid-19 patients. The funds were awarded as part of the federal government’s Strategic Innovation Fund after reviewing Edesa’s drug technology and strategies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.